Nitric oxide (NO) system
also: NO signalling, nitric oxide pathway, eNOS pathway, nitric oxide synthase system
A gasotransmitter signalling system in which eNOS, iNOS, and nNOS enzymes convert L-arginine to nitric oxide, regulating vascular tone, platelet aggregation, and tissue repair.
Nitric oxide (NO) is a short-lived, membrane-permeable gaseous signalling molecule produced enzymatically from L-arginine by nitric oxide synthase (NOS) enzymes. Three NOS isoforms exist: endothelial NOS (eNOS, expressed constitutively in blood vessel endothelium), neuronal NOS (nNOS, expressed in nervous tissue), and inducible NOS (iNOS, upregulated in macrophages and other cells during inflammation). NO acts primarily by activating soluble guanylate cyclase (sGC) in target cells, raising cyclic GMP (cGMP) and triggering downstream relaxation of vascular smooth muscle, inhibition of platelet aggregation, and modulation of gene expression.
Why it matters in peptide research
The NO system is a major effector of tissue perfusion and repair. When eNOS is activated in endothelial cells — by shear stress, VEGF, bradykinin, or peptide signals — the resulting NO diffuses into adjacent smooth muscle, relaxes vessel walls, and increases blood flow to injured tissue. This vasodilatory response is essential for delivering nutrients, oxygen, and immune cells to healing wounds. NO also promotes angiogenesis by stabilising HIF-1α and stimulating VEGF expression, adding another layer of repair-supporting activity.
BPC-157, a pentadecapeptide fragment of body protection compound, has been extensively studied in rat injury models and consistently shows NO-dependent protective effects. Proposed mechanisms include upregulation of eNOS expression, enhanced NO-dependent smooth muscle relaxation in the vasculature supplying injured sites, and potentiation of VEGF receptor signalling. In models where NOS inhibitors such as L-NAME are co-administered, BPC-157's pro-healing effects are blunted — evidence consistent with NO pathway dependence rather than a NOS-independent mechanism.
The NO system has a biphasic relationship with inflammation: at low, eNOS-derived concentrations NO is generally anti-inflammatory and cytoprotective; at high, iNOS-derived concentrations in activated macrophages, NO contributes to oxidative stress through peroxynitrite formation. Peptides that selectively modulate eNOS without driving iNOS upregulation are therefore of greater therapeutic interest.
Peptides / stacks that act on this
- BPC-157 — pentadecapeptide with documented NO pathway dependence across multiple preclinical injury models; effects on eNOS expression and VEGF-NO axis are proposed core mechanisms
Reading tip
"Nitric oxide booster" is a term widely used in sports nutrition marketing, typically referring to L-arginine or L-citrulline supplementation. The mechanistic connection between oral L-arginine and meaningful eNOS activation is much weaker than the marketing implies — substrate availability is rarely rate-limiting for eNOS in healthy individuals, and the enzyme's activity is primarily regulated post-translationally by phosphorylation and calmodulin binding.